Gilead Sciences (NASDAQ:GILD – Free Report) had its price objective boosted by The Goldman Sachs Group from $125.00 to $130.00 in a report published on Friday,MarketScreener reports. The brokerage currently has a neutral rating on the biopharmaceutical company’s stock.
Several other brokerages have also issued reports on GILD. Oppenheimer increased their target price on Gilead Sciences from $128.00 to $165.00 and gave the stock an “outperform” rating in a research report on Wednesday, February 11th. BMO Capital Markets increased their target price on Gilead Sciences from $135.00 to $150.00 and gave the stock an “outperform” rating in a research report on Monday, January 26th. Daiwa Securities Group increased their target price on Gilead Sciences from $129.00 to $161.00 and gave the stock an “outperform” rating in a research report on Wednesday, February 25th. Wolfe Research increased their target price on Gilead Sciences from $155.00 to $170.00 and gave the stock an “outperform” rating in a research report on Thursday, February 12th. Finally, Rothschild & Co Redburn increased their target price on Gilead Sciences from $159.00 to $170.00 and gave the stock a “buy” rating in a research report on Tuesday, February 17th. Twenty-four equities research analysts have rated the stock with a Buy rating and four have assigned a Hold rating to the company. According to MarketBeat, the company currently has a consensus rating of “Moderate Buy” and an average target price of $157.35.
Get Our Latest Report on Gilead Sciences
Gilead Sciences Trading Down 0.7%
Gilead Sciences (NASDAQ:GILD – Get Free Report) last released its quarterly earnings results on Tuesday, February 10th. The biopharmaceutical company reported $1.86 EPS for the quarter, beating analysts’ consensus estimates of $1.83 by $0.03. Gilead Sciences had a return on equity of 49.46% and a net margin of 28.90%.The business had revenue of $7.93 billion during the quarter, compared to analyst estimates of $7.68 billion. During the same quarter in the prior year, the company posted $1.90 EPS. Gilead Sciences’s quarterly revenue was up 4.7% compared to the same quarter last year. Gilead Sciences has set its FY 2026 guidance at 8.450-8.850 EPS. Analysts predict that Gilead Sciences will post 7.95 EPS for the current year.
Gilead Sciences Increases Dividend
The business also recently disclosed a quarterly dividend, which was paid on Monday, March 30th. Investors of record on Friday, March 13th were given a dividend of $0.82 per share. This is a boost from Gilead Sciences’s previous quarterly dividend of $0.79. The ex-dividend date of this dividend was Friday, March 13th. This represents a $3.28 dividend on an annualized basis and a yield of 2.4%. Gilead Sciences’s dividend payout ratio is 48.45%.
Insider Buying and Selling
In related news, CFO Andrew D. Dickinson sold 3,000 shares of the firm’s stock in a transaction that occurred on Tuesday, February 17th. The stock was sold at an average price of $154.43, for a total transaction of $463,290.00. Following the completion of the transaction, the chief financial officer owned 167,779 shares of the company’s stock, valued at $25,910,110.97. This trade represents a 1.76% decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink. Also, CEO Daniel Patrick O’day sold 115,640 shares of the firm’s stock in a transaction that occurred on Friday, January 23rd. The shares were sold at an average price of $135.00, for a total value of $15,611,400.00. Following the transaction, the chief executive officer directly owned 566,698 shares of the company’s stock, valued at approximately $76,504,230. This trade represents a 16.95% decrease in their position. The disclosure for this sale is available in the SEC filing. Insiders sold 299,280 shares of company stock worth $42,920,450 in the last 90 days. Corporate insiders own 0.30% of the company’s stock.
Institutional Inflows and Outflows
Institutional investors and hedge funds have recently added to or reduced their stakes in the stock. Vanguard Group Inc. boosted its stake in Gilead Sciences by 1.8% during the 4th quarter. Vanguard Group Inc. now owns 121,097,336 shares of the biopharmaceutical company’s stock valued at $14,863,487,000 after purchasing an additional 2,113,692 shares during the last quarter. State Street Corp boosted its stake in Gilead Sciences by 1.9% during the 4th quarter. State Street Corp now owns 60,240,518 shares of the biopharmaceutical company’s stock valued at $7,393,921,000 after purchasing an additional 1,151,213 shares during the last quarter. Price T Rowe Associates Inc. MD boosted its stake in Gilead Sciences by 4.5% during the 4th quarter. Price T Rowe Associates Inc. MD now owns 27,698,660 shares of the biopharmaceutical company’s stock valued at $3,399,734,000 after purchasing an additional 1,195,269 shares during the last quarter. Bank of America Corp DE boosted its stake in Gilead Sciences by 15.2% during the 4th quarter. Bank of America Corp DE now owns 23,121,620 shares of the biopharmaceutical company’s stock valued at $2,837,948,000 after purchasing an additional 3,046,688 shares during the last quarter. Finally, Norges Bank purchased a new stake in Gilead Sciences during the 4th quarter valued at $2,617,152,000. Institutional investors own 83.67% of the company’s stock.
Gilead Sciences News Summary
Here are the key news stories impacting Gilead Sciences this week:
- Positive Sentiment: Gilead received all required regulatory approvals to close its acquisition of Arcellx and extended the tender offer—this accelerates Gilead’s cell‑therapy/oncology strategy and reduces deal execution risk. Gilead Receives All Required Regulatory Approvals for the Acquisition of Arcellx and Extends Tender Offer
- Positive Sentiment: Morgan Stanley raised its price target to $175 and kept an Overweight rating, signaling confidence in Gilead’s forward growth profile ahead of Q1 results. Morgan Stanley Adjusts Gilead Sciences, Inc. (GILD) Outlook Ahead of Q1 Earnings
- Positive Sentiment: High‑profile endorsements: Wells Fargo reiterated a Buy, and Jim Cramer said on-air he’d “hold on to it,” both supporting investor sentiment. Wells Fargo Sticks to Their Buy Rating for Gilead Sciences (GILD) Jim Cramer on Gilead Sciences: “I’d Hold On to It”
- Neutral Sentiment: Insider transactions: two insiders (including the CFO) sold small blocks under pre‑arranged 10b5‑1 plans—typical liquidity moves that are not clear signals of new company problems. Gilead Sciences (NASDAQ:GILD) Insider Sells $422,880.00 in Stock
- Neutral Sentiment: Goldman Sachs nudged its target modestly higher but kept a Neutral rating—mixed analyst signals leave upside expectations uneven. Goldman Sachs Adjusts Gilead Sciences Price Target to $130 from $125; Maintains Neutral Rating
- Neutral Sentiment: Upcoming quarterly earnings and recent analyst/valuation pieces are increasing attention and short‑term volatility as investors position around product trends and guidance. Gilead Sciences (GILD) Expected to Announce Quarterly Earnings on Thursday
- Negative Sentiment: RBC flagged weaker‑than‑expected persistence for Gilead’s recently launched HIV drug nine months after launch—this could temper upside to long‑term revenue assumptions for the franchise. Gilead Sciences’ HIV Drug Shows Weaker-Than-Expected Persistence Nine Months After Launch, RBC Says
- Negative Sentiment: Zacks trimmed Q1–Q4 FY2026 EPS estimates, lowering near‑term earnings expectations and adding downside risk to consensus. Gilead Sciences, Inc. (GILD) Is a Trending Stock: Facts to Know Before Betting on It
- Negative Sentiment: Broad health‑care sector weakness is pressuring GILD alongside stock‑specific news, amplifying the intraday decline. Sector Update: Health Care Stocks Decline Late Afternoon
Gilead Sciences Company Profile
Gilead Sciences, Inc, founded in 1987 and headquartered in Foster City, California, is a biopharmaceutical company focused on the discovery, development and commercialization of medicines in areas of high unmet medical need. The company initially built its reputation in antiviral therapies and has since expanded into oncology, cell therapy and inflammatory diseases. Gilead operates a global research and commercial organization, conducting clinical development and selling medicines in markets around the world.
Gilead’s product portfolio is anchored by antiviral therapies for HIV and viral hepatitis.
See Also
Receive News & Ratings for Gilead Sciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Gilead Sciences and related companies with MarketBeat.com's FREE daily email newsletter.
